Information  X 
Enter a valid email address

OncimmuneHldg Ord 1P (ONC)

Date Time Source Announcement
05 May 2022 5:32 pm
RNS
Holding(s) in Company
03 May 2022 6:10 pm
RNS
Holding(s) in Company
26 Apr 2022 4:26 pm
RNS
Holding(s) in Company
21 Apr 2022 7:00 am
RNS
Queen's Award for Enterprise in Innovation 2022
14 Apr 2022 12:24 pm
RNS
Exercise of Options, PDMR Dealing and TVR
08 Apr 2022 7:00 am
RNS
Two further ImmunoINSIGHTS contracts signed
04 Apr 2022 2:43 pm
RNS
Holding(s) in Company
29 Mar 2022 4:46 pm
RNS
Exercise of Options, PDMR Dealing and TVR
18 Mar 2022 3:01 pm
RNS
Holding(s) in Company
16 Mar 2022 7:00 am
RNS
Block Listing Six Monthly Return
15 Mar 2022 7:00 am
RNS
Exercise of Warrants and Total Voting Rights
09 Mar 2022 4:08 pm
RNS
Holding(s) in Company
07 Mar 2022 2:10 pm
RNS
PDMR Dealing
  7:00 am
RNS
Follow-on contract to validate previous profiling
04 Mar 2022 7:00 am
RNS
ImmunoINSIGHTS contract signed with global pharma
01 Mar 2022 7:00 am
RNS
ImmunoINSIGHTS and Synexa partnership
28 Feb 2022 7:05 am
RNS
Interim Results
  7:00 am
RNS
Contract signed with Verily Life Sciences
25 Feb 2022 7:00 am
RNS
Notice of Half Year Results
21 Feb 2022 3:14 pm
RNS
Holding(s) in Company
17 Feb 2022 7:00 am
RNS
EarlyCDT Lung approved and adopted in Aragon Spain
15 Feb 2022 7:00 am
RNS
ImmunoINSIGHTS commercial update
31 Dec 2021 7:00 am
RNS
Results from COVID-19 autoantibody profiling panel
24 Dec 2021 7:00 am
RNS
PDMR Dealing
22 Dec 2021 11:10 am
RNS
Grant of Options and PDMR Dealing
21 Dec 2021 11:34 am
RNS
PDMR Dealing
  7:00 am
RNS
ImmunoINSIGHTS commercial update
07 Dec 2021 7:00 am
RNS
Commercial momentum in ImmunoINSIGHTS
26 Nov 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
  10:36 am
RNS
Results of Annual General Meeting
03 Nov 2021 7:00 am
RNS
Notice of AGM and posting of Annual Report
02 Nov 2021 7:00 am
RNS
Full year results and progress update
  7:00 am
RNS
Change of Adviser
27 Oct 2021 4:35 pm
RNS
Price Monitoring Extension
25 Oct 2021 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Notice of Full Year results
20 Sep 2021 7:00 am
RNS
Agreement with pharma company to profile patients
15 Sep 2021 11:08 am
RNS
Block Listing Six Monthly Return
23 Aug 2021 7:00 am
RNS
Three-year follow-up data for the ECLS trial
23 Jul 2021 7:00 am
RNS
Agreement signed with major cancer center
22 Jul 2021 7:00 am
RNS
Validation of ImmunoINSIGHTS service in COVID-19
01 Jul 2021 7:00 am
RNS
Total Voting Rights
08 Jun 2021 7:00 am
RNS
Full Year Trading Update
28 May 2021 7:30 am
RNS
Notice of FY21 Trading Update
05 May 2021 7:03 am
RNS
Return of China Rights to EarlyCDT
04 May 2021 12:23 pm
RNS
Total Voting Rights
08 Apr 2021 7:00 am
RNS
Holding(s) in Company
07 Apr 2021 2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
06 Apr 2021 1:48 pm
RNS
Block Listing Six Monthly Return
  7:00 am
RNS
Agreements signed with Roche and Cedars-Sinai
  7:00 am
RNS
Holding(s) in Company
01 Apr 2021 7:00 am
RNS
Holding(s) in Company
25 Mar 2021 2:01 pm
RNS
Result of Oversubscribed Equity Placing
  7:45 am
RNS
Launch of Equity Placing via Accelerated Bookbuild
15 Mar 2021 7:00 am
RNS
Issue of Equity and Total Voting Rights
01 Mar 2021 7:00 am
RNS
Total Voting Rights
15 Feb 2021 7:00 am
RNS
Interim Results

a d v e r t i s e m e n t